Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

Diabetes

Volumn 49, Issue 4, 2000, Pages 633-639

  Kruszynska, Yolanta T ^a,c   Yu, Joseph G ^a   Olefsky, Jerrold M ^a   Sobel, Burton E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; HEMOGLOBIN A1C; INSULIN; NEUTRAL INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TROGLITAZONE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE UTILIZATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PLASMA; PRIORITY JOURNAL; RISK FACTOR;

EID: 0034126428     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.49.4.633     Document Type: Article

References (46)

1. DeFronzo RA, Ferrannini E: Insulin resistance: a mutifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
3. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B: Plasminogen activator inhibitor in plasma: risk factors for recurrent myocardial infarction. Lancet ii:3-9, 1987
4. Juhan-Vague I, Alessi MC, Vague P: Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 34:457-462, 1991
5. Wiman B, Hamsten A: The fibrinolytic enzyme system and its role in the etiology of thrombo-embolic disease. Semin Thromb Hemost 26:207-216, 1990
6. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C: Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 38:913-915, 1989
7. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C: Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabetes Metab 13:331-336, 1987
8. MoGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43:104-109, 1994
9. Juhan-Vague, I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P: Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients: relationship with plasma insulin. Thromb Haemost 61:370-373, 1989
10. Lormeau B, Aurousseau MH, Valensi P, Paries J, Attali JR: Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients. Metabolism 46:1074-1079, 1997
11. Auwerx J, Bouillon R, Collen D, Geboers J: Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8:68-72, 1988
12. Garcia-Frade LJ, De la Calle H, Torrado MC, Lara JI, Cuellar L, Avello AG: Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus. Thromb Res 59:51-59, 1990
13. Gray RP, Yudkin JS, Patterson DLH: Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic subjects. Br Heart J 69:228-232, 1993
14. Panahloo A, Yudkin JS: Diminished fibrinolysis in diabetes mellitus and its implications for diabetic vascular disease. J Cardiovasc Risk 4:91-99, 1997
15. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
16. Kooistra T, Bosma PJ, Tons HAM, van den Berg AP, Meyer P, Princen HMG: Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 62:723-728, 1989
17. Schneider DJ, Absher PM, Ricci MA: Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells. Circulation 96:2868-2876, 1997
18. Nordt TK, Sawa H, Fujii S, Sobel BE: Induction of plasminogen activator inhibitor type 1 (PAI-1) by proinsulin and insulin in vivo. Circulation 91:764-770, 1995
19. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I: Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46:860-867, 1997
20. Koistinen H, Ebeling P, Tuominen JA, Vallier P, Laville M, Koivisto VA, Vidal H: Subcutaneous adipose tissue PAI-1 gene expression has a diurnal variation and it correlates with obesity and insulin resistance (Abstract). Diabetes 48 (Suppl. 1):A313, 1999
21. Grant PJ, Kruithof E, Felley CP, Felber IP, Bachman F: Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 79:513-516, 1990
22. Vuorinen-Markkola H, Puhakainen I, Yki-Jarvinen H: No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Haemost 67:117-120, 1992
23. Landin K, Tengborn L, Chmielewska J, von Schenck H, Smith U: The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost 65:130-133, 1991
24. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ: Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 47:290-293, 1998
25. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
26. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
27. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double blind, placebo-controlled trial. Ann Intern Med 128:176-185, 1998
28. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872, 1998
29. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
30. Panahloo A, Mohamed-Ali V, Andres C, Denver AE, Yudkin JS: Effects of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes. Metabolism 47:637-643, 1998
31. Tafuri SR: Troglitazone enhances differentiation, basal glucose uptake, and Glut 1 protein levels in 3T3-L1 adipocytes. Endocrinology 137:4706-4712, 1996
32. Spiegelman BM: PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998
33. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
34. Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti JR, Olefsky JM: Skeletal muscle peroxisome proliferator-aclivated receptor-γ expression in obesity and non-insulin-dependent diabetes mellitus. J Clin Invest 101:543-548, 1998
35. Desbuquois B, Aurbach GD: Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 33:732-738, 1971
36. Kluft C, Verheijen JH: Leiden fibrinolysis working party: blood coagulation and handling procedures for assessment of tissue-type plasminogen activator [t-PA] and plasminogen activator inhibitor-1 [PAI-1]. Fibrinolysis 4 (Suppl. 2):155-161, 1990
37. Steele R: Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420-430, 1959
38. Wolfe RR: Tracers in Metabolic Research: Radioisotope/Mass Spectrometry Methods. New York, Liss, 1984, p. 81-101
39. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I: Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 96:761-768, 1997
40. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS: Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 10:27-32, 1993
41. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2108-2116, 1997
42. Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Segheri G, Ferrannini E: Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Pharmacol Ther 62:194-202, 1997
43. Schwartz S, Raskin P, Fonseca V, Graveline JF: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus: Troglitazone and Exogenous Insulin Study Group. N Engl J Med 338:861-866, 1998
44. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y: Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2:800-803, 1996
45. Kluft C, Jie AFH, Rijken DC, Verheijen JH: Daytime fluctuations in blood of tissue-type plasminogen activator (tPA) and its fast-acting inhibitor (PAI-1). Thromb Haemost 59:329-332, 1988
46. Angleton P, Chandler WL, Schmer G: Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 79:101-106, 1989